CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kineta Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kineta Inc
7683 Se 27Th Street, Suite 481
Phone: (206) 378-0400p:206 378-0400 MERCER ISLAND, WA  98040  United States Ticker: KAKA
Business Summary
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President Craig W.Philips 63 12/16/2022 12/16/2022
Chief Financial Officer Keith A.Baker 56 12/16/2022 12/16/2022
Executive Vice President - Investor Relations and Business Development JacquesBouchy 54 10/1/2022 10/1/2022
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Yumanity Therapeutics, Inc. 790 Memorial Drive Cambridge MA United States
Kineta, Inc. 219 Terry Ave N Ste 300 Seattle WA United States

Business Names
Business Name
KA
Kineta Chronic Pain, LLC
Kineta Operating, LLC
5 additional Business Names available in full report.

General Information
Number of Employees: 11 (As of 12/31/2023)
Outstanding Shares: 10,962,460 (As of 3/18/2024)
Shareholders: 270
Stock Exchange: NASD
Federal Tax Id: 000980301
Fax Number: (302) 636-5454
Email Address: info@proteostasis.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024